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A 70-year-old female was seen in the office for evalua- 
tion of non-healing skin lesions. She had a history of 
insulin-dependent diabetes mellitus for 13 years and was 
well until 6 months previous to presentation, when she 
developed raised erythematous lesions initially on her 
left arm and subsequently involving both upper extrem- 
ities and the posterior thoracic wall. 
She was seen by several physicians and was treated 
with antifungal and steroid-containing creams without 
any improvement. She had no fever, sore throat, or acute 
joint pain. She had history of long-standing osteoarthritis. 
She had been born and raised in central New Jersey. 
She travelled to China about 12 years prior to this inci- 
dent, where she stayed for 2 weeks in both rural and 
urban areas. Three years before presentation she had trav- 
elled to Hawaii for vacation and stayed in major city 
hotels. 
Pertinent physical examination revealed body tem- 
perature, 36°C; pulse, 80 beats per minute; respiratory 
rate, 16 per minute; blood pressure, 190/80 mm Hg. There 
were indurated erythematous lesions on both upper 
extremities and the posterior thoracic wall (Figure 1). 
There were no oral lesions, no adenopathy, and no abnor- 
malities of peripheral nerves. The rest of physical exam- 
ination was unremarkable. 
Significant laboratory findings showed hemoglobin of 
14.5 g/dL and white blood cell count of 9200/ mm3 with 
normal differential count. Blood chemistry values were 
normal except for a slightly high serum glucose level of 
151 mg/dL (normal range [N] = 70- 150 mg/dL) and a 
cholesterol level of 231 mg/dL (N = 142-200 mg/dL). 
The initial differential diagnosis included sarcoido- 
sis, lymphoma, and vasculitis. However, hypoesthesia over 
the skin lesions was noted, and a diagnosis of leprosy 
was entertained by the infectious disease physician 
despite the absence of a clear exposure history. A full- 
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thickness biopsy of skin was performed and demon- 
strated granulomatous dermatitis and an overwhelming 
number of acid-fast organisms by both Ziehl-Neelsen and 
Fite stains consistent with the diagnosis of lepromatous 
leprosy (Figure 2). The patient was treated with dapsone 
and rifampin. Ten months later, her skin lesions wors- 
ened. This was considered to be secondary to a hyper- 
sensitivity phenomenon with reversal reaction. A repeat 
skin biopsy was performed and showed a chronic inflam- 
matory infiltrate with foamy macrophages. Fite stains 
again revealed numerous small acid-fast bacilli with no 
apparent microorganism decrease within cutaneous 
nerves compared to the initial biopsy This was consistent 
with a reversal reaction or failure of therapy. Additional 
treatment with clofazamine and minocycline was started. 
The patient also was treated with oral prednisone, 60 mg 
daily initially, with subsequent tapering doses for a pos- 
sible reversal reaction related to her therapy. Follow-up 
showed no new skin lesions and satisfactory regression 
of existing lesions. 
Eighteen months later, the patient developed cough 
and fever. Chest radiograph revealed an infiltrate, and she 
was treated for pneumonia with apparent improvement. 
Six months later, she sustained fracture of the pelvis from 
Figure 1. Hypoesthetic raised etythematous lesions on the dorsum 
of the hand. 
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Figure 2. Skin biopsy showing numerous leprosy bacilli. (Fite stain, 
original magnification X400). 
a fall. She had persistent mild cough. Chest radiograph 
showed increased markings in the left mid and lower 
lung fields. Bronchoscopic biopsy showed organisms in 
the lung parenchyma consistent with Cryptococcus neo- 
formans. Serum cryptococcal antigen was positive at a 
dilution of 1:512. The patient was treated with intra- 
venous amphotericin followed by oral fluconazole with 
satisfactory improvement in the respiratory symptoms. 
Follow-up chest radiograph showed significant improve- 
ment, and serum cryptococcal antigen declined. Anti- 
leprosy medications were discontinued after total 
treatment of 2.5 years. 
The patient’s human immunodeficiency virus (HIV) 
serology was negative. Interestingly, her T-cell subset stud- 
ies were completely normal when leprosy was diagnosed, 
but did deteriorate during steroid therapy (Table l), with 
a dramatic decline in both CD4 and CDS cells. However, 
after pulmonary cryptococcal infection was diagnosed, 
during treatment with amphotericin and small tapering 
doses of prednisone, her T-cell subset studies had reverted 
to normal. 
DISCUSSION 
Leprosy or Hansen’s disease @ID) presents a major pub- 
lic health problem, particularly in the Third World 
Table 1. Profile of T Lymphocytes 
in Patient Diagnosed with Leprosy 
CD3 CD3 + CD4 CD3/CD8 
Date (N=1654?449) (N=1080?370) (N=507?785) 
February 1995 1619 (74.9%) 945 (43.7%) 603 (27.9%) 
January 1996 362 (69.9%) 192 (36.9%) 148 (28.5%) 
January 1998 1290 (76.0%) 810 (63.0%) 447 (35.0%) 
N = normal range. 
countries. In 1991,5.5 million active cases were reported 
throughout the world. l 
In the United States there have been approximately 
6000 known cases.* The incidence increased in the 1980s 
compared to 1950s3,* and in 1996,112 newly diagnosed 
cases were reported to the Centers for Disease Control 
and Prevention (CDC).5 The majority of these patients 
were foreign-born,’ but 31 cases per year of HD among 
native-born persons were reported between 1970 and 
1981. Most of these individuals were born in three states: 
Texas (56%), Louisiana (14%) and California (4%). In 
Hawaii, 255 cases of HD were reported during the years 
1951 to 1981 .6 Indigenous cases of HD still are being 
reported from Louisiana, California, Hawaii, and New York 
City.’ 
The case reported here raises some interesting epi- 
demiologic questions. The patient was born and lived in 
central New Jersey and travelled to Hawaii and China for 
brief periods, but she had no contact with persons known 
to have HD. New Jersey is not known to have any 
endemic leprosy focus. In the past 10 years, 17 cases of 
HD have been reported to the New Jersey Department 
of Health and Senior Services (State Department of 
Health. Personal communication). To the authors’ knowl- 
edge, all these individuals, except for the patient reported 
here, were immigrants. 
In a report of 100 cases of HD in New York City, 99% 
were foreign-born and presumably acquired infection 
while abroad.* Interestingly, in one report, 70% of native- 
born citizens of the United States with HD had no history 
of leprosy contacts.6 The mechanisms of transmission of 
Mycobacterium Zeprae, the causative agent of HD, still 
are unclear. It is believed that human-to-human trans- 
mission probably occurs through the respiratory route 
by airborne droplets from the nasal mucosa.“,“’ Skin con- 
tact no longer is considered to be important for trans- 
mission, although trauma to the skin might provide a 
route for direct transmission. Although not proven, obser- 
vations from Louisiana, Texas, and Mexico suggest that 
HD may be acquired from contact with armadillos.” Since 
armadillos are not present in New Jersey, this is an 
unlikely source of M. Zeprue in the reported case. 
Repeated exposure to patients with active leprosy has 
been considered necessary for human-to-human trans- 
mission, but this theory may not be altogether true. Even 
brief exposure might be sufficient to contract the infec- 
tion if large numbers of viable M. Zeprue are shed by the 
patient.‘* 
The patient reported here could have been exposed 
to patients with active leprosy while in China, Hawaii, or 
even in New Jersey without her knowledge and then 
years later developed the disease when her specific 
immunity to M. leprae declined. However, casual contact 
resulting in transmission of the disease is not important 
from a public health point of view since there has been 
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no documented secondary transmission from imported 
cases within the continental United States.‘* 
This patient was 70 years of age at the time of diag- 
nosis. The existence of subclinical or asymptomatic lep- 
rosy has been postulated, suggesting that late reactivation 
of the disease may occur because of declining immune 
function in older individuals.13 Among indigenous cases 
of leprosy reported from Louisiana, three patients had 
some type of potentially immunosuppressive illness, 
including Hodgkin disease, cervical carcinoma, and dia- 
betes mellitus, but there were no specific data on their 
immunologic status.” There are no large studies to indi- 
cate that HD is more common or worse in compromised 
hosts, including those with HIV” Studies during World 
War II suggested worsening of leprosy in malnourished 
individuals,‘4,‘5 but convincing data are lacking. 
Patients with HD often are not anergic and respond 
normally to intradermal skin tests.” However, there is 
evidence of specific anergy to M. leprae in patients with 
lepromatous leprosy, perhaps as a result of the illness 
rather than as a causative factor.“.‘* This patient had 
normal T-cell studies at the time of diagnosis, although 
specific studies to determine anergy to M. leprae were 
not done. In active skin lesions, T-lymphocyte subsets 
appear to vary depending on the type of leprosy. Helper 
cells predominate in tuberculoid skin lesions, whereas 
in the lepromatous type, the majority are suppressor 
cells. In this patient, specific studies to determine the 
T-lymphocyte subtype predominance were not done. 
There was another interesting feature in this case. After 
HD-related skin lesions healed, the patient developed 
pulmonary cryptococcosis. Patients with cell-mediated 
immune dysfunction are at increased risk for crypto- 
coccosis. This patient’s susceptibility to cryptococcal 
infection may have resulted from the steroid therapy 
that was accompanied by reduction in circulating T 
cells. Subsequently, during treatment for cryptococcal 
disease, her peripheral lymphocyte studies were within 
the normal range, but intradermal reaction to delayed- 
type antigens, such as purified protein derivative (PPD), 
was not performed. 
Genetic factors have been mentioned as influencing 
susceptibility to leprosy. I9 A study done among the 
Karimui people of New Guinea demonstrated that the 
risk for contracting leprosy in the offspring of parents 
with leprosy was not influenced by the severity or infec- 
tivity of the disease but was higher where there was a 
family history of leprosy. Specific human leukocyte anti- 
gen haplotypes may determine the clinical forms of lep- 
rosy, influencing the helper T-lymphocyte, and thereby, the 
specific immune response.zo~21 
Most cases in native-born patients in the United States 
are the multibacillary form of the disease,6 in which a 
significant number of acid-fast bacilli are present in skin 
biopsies, as was evident in the case presented here. This 
may represent a poor cellular response to M. Zeprae. 
The clinical features of various forms of HD, includ- 
ing lepromatous, tuberculoid, and borderline cases have 
been well described.9a22 Misdiagnosis is common, even in 
patients from endemic areas, particularly if those with 
lepromatous type leprosy present with only chronic non- 
healing skin lesions without typical leonine facies, defor- 
mities of extremities, or nerve abnormalities. Diagnosis 
is even more difficult in indigenous cases without any 
history of contact with patients known to have leprosy. 
The diagnosis of HD should be considered in any per- 
son presenting with unexplained skin lesions, and a care- 
ful assessment should be made for sensory loss in the 
lesions; however, in patients with lepromatous leprosy, 
sensory loss may not be present until later stages of the 
disease. Consequently a careful search should be made, 
looking for nodules in the ears, nose, and eyebrows and 
for subtle eye changes. Eye changes in lepromatous lep- 
rosy may include partial or complete loss of eyebrows 
(madarosis), persistent red eye or incomplete closure of 
eyelids due to seventh nerve p&y (lagophthalmosis).92 
Skin lesions often worsen after chemotherapy, owing 
to reversal or erythema nodosum leprosum (ENL) reac- 
tion. Reversal reactions represent changes in the cell- 
mediated immunity in the skin lesions, with proliferation 
of T lymphocytes and worsening of inflammatory 
response, and may worsen the clinical picture of border- 
line leprosy. There may even be increased bacterial pro- 
liferation locally in the skin lesions.” Erythema nodosum 
leprosom reaction often follows chemotherapy in all 
forms of leprosy and not only may complicate the skin 
lesions with tender nodules or extensive ulceration but 
also may be associated with development of systemic 
reactions including fever, lymphadenopathy, neuritis, 
glomerulonephritis, and secondary amyloidosis.** The 
mechanism of ENL reaction involves immune complex 
formation in skin lesions that enhance helper T cells.25 
The differential diagnosis of skin lesions in a patient 
with HD includes superficial fungus infection, Kaposi’s 
sarcoma, sarcoidosis, lymphoma, lupus vulgaris, syphilis, 
and granuloma annulare. A skin biopsy from the edge of 
the lesion or nasal smears for acid-fast bacilli are the only 
methods for establishing the diagnosis. 
Table 2 enumerates the various drugs currently avail- 
able in the United States for treatment of HD.z6x27 It is 
preferable that physicians with experience with the disease 
should evaluate the patient at least initially and then peri- 
odically if there are adverse drug reactions or failure of 
therapy owing to drug resistance. In general, multiple 
drugs, including dapsone, rifampin with or without clo- 
fazimine, are necessary to prevent drug resistance and 
should be continued for at least 24 months. The clinical 
presentations of drug reactions often are complex and 
require prompt and careful evaluation. Since adverse reac- 
tions to treatment in patients with lepromatous leprosy 
include type-1 reversal reaction and ENL, repeat skin biopsy 
may be necessary to determine the type of reaction. 
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Table 2. Drugs for Treatment of Leprosy 
Usual Regimen Other Useful Drugs 
Dapsone Minocycline 
Rifampin Ofloxacin 
Clofazimine Pefloxacin 
Clarithromycin 
Adjunct therapy with corticosteroids may be necessary 
and thalidomide has been advocated for men with ENL.28 
SUMMARY 
Despite the overall decline in number of leprosy cases in 
the United States, small numbers of patients with the dis- 
ease continue to be reported, predominantly among immi- 
grant populations. Occasional cases occur among 
native-born American residents, predominantly from the 
southern United States. The source of the reservoir and 
transmission among indigenous HD cases remains unex- 
plained, although armadillos in the state of Texas and 
Louisiana have been implicated. Since most patients 
among the indigenous cases occur in older age groups, 
the possibility of reactivation of the disease through 
immunosenescence has been raised. In most patients, 
unfamiliarity with the clinical picture of HD among physi- 
cians in the United States accounts for delayed or incor- 
rect diagnosis. High index of suspicion in a patient with 
unusual skin lesions, particularly with sensory loss, should 
be followed by a biopsy looking for the characteristic 
histologic changes found in various forms of leprosy. 
Reversal reactions and erythema nodosum leprosum are 
relatively frequent complications of treatment. Treatment 
and periodic follow-up of these patients should be done, 
preferably by physicians with experience with the disease 
entity. 
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